Digestive and Liver Disease
Volume 41, Issue 8 , Pages 605-608 , August 2009

Clinical significance of serum tumour M2-PK and CA19-9 detection in the diagnosis of cholangiocarcinoma

  • Y.G. Li

      Affiliations

    • Department of Laboratory, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
    • Corresponding Author InformationCorresponding author.
    • ,
  • N. Zhang

      Affiliations

    • Tianjin Research Center of Basic Medical Science, Tianjin 300070, China

Received 2 June 2008 ,Accepted 13 November 2008.

References 

  1. Kobayashi M, Ikeda K, Saitoh S, Suzuki F, Tsubota A, Suzuki Y, et al. Incidence of primary cholangiocellular carcinoma of the liver in Japanese patients with hepatitis C virus-related cirrhosis. Cancer. 2000;88:2471–2477
  2. Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case–control study. Gastroenterology. 2005;128:620–626
  3. Eigenbrodt E, Reinacher M, Scheefers-Borchel U, Scheefers H, Friis R. Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells. Crit Rev Oncog. 1992;3:91–115
  4. Eigenbrodt E, Kallinowski F, Ott M, Mazurek S, Vaupel P. Pyruvate kinase and the interaction of amino acid and carbohydrate metabolism in solid tumors. Anticancer Res. 1998;18:3267–3274
  5. Eigenbrodt E, Basenau D, Holthusen S, Mazurek S, Fischer G. Quantification of tumor type M2 pyruvate kinase (Tu M2-PK) in human carcinomas. Anticancer Res. 1997;17:3153–3156
  6. Oremek GM, Teigelkamp S, Kramer W, Eigenbrodt E, Usadel KH. The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma. Anticancer Res. 1999;19:2599–2601
  7. Lüftner D, Mesterharm J, Akrivakis C, Geppert R, Petrides PE, Wernecke KD, et al. Tumor type M2 pyruvate kinase expression in advanced breast cancer. Anticancer Res. 2000;20:5077–5082
  8. Schneider J, Morr H, Velcovsky HG, Weisse G, Eigenbrodt E. Quantitative detection of tumor M2-pyruvate kinase in plasma of patients with lung cancer in comparison to other lung diseases. Cancer Detect Prev. 2000;24:531–535
  9. Hardt PD, Ngoumou BK, Rupp J, Schnell-Kretschmer H, Kloer HU. Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastro-intestinal cancer. Anticancer Res. 2000;20:4965–4968
  10. Schulze G. The tumor marker tumor M2-PK: an application in the diagnosis of gastrointestinal cancer. Anticancer Res. 2000;20:4961–4964
  11. Burgos San Juan L. Cholangiocarcinoma. Rev Med Child. 2008;136:240–248
  12. Farhat MH, Shamseddine AI, Tawil AN, Berjawi G, Sidani C, Shamseddeen W, et al. Prognostic factors in patients with advanced cholangiocarcinoma: role of surgery, chemotherapy and body mass index. World J Gastroenterol. 2008;14:3224–3230
  13. Lempinen M, Isoniemi H, Mäkisalo H, Nordin A, Halme L, Arola J, et al. Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures. J Hepatol. 2007;47:677–683
  14. Pezzilli R, Migliori M, Morselli-Labate AM, Campana D, Ventrucci M, Tomassetti P, et al. Diagnostic value of tumor M2-pyruvate kinase in neuroendocrine tumors. A comparative study with chromogranin A. Anticancer Res. 2003;23:2969–2972

PII: S1590-8658(08)00706-8

doi: 10.1016/j.dld.2008.11.010

Digestive and Liver Disease
Volume 41, Issue 8 , Pages 605-608 , August 2009

Article Tools

* Image Usage & Resolution